SciELO - Scientific Electronic Library Online

vol.38 número1  suppl.1 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Acta Neurológica Colombiana

versión impresa ISSN 0120-8748versión On-line ISSN 2422-4022


PRADILLA, Oscar Enrique et al. Recommendations on the use of the antiCGRP monoclonal antibodies for migraine prophylaxis on behalf of the Colombian Association of Neurology. Acta Neurol Colomb. [online]. 2022, vol.38, n.1, suppl.1, pp.1-22.  Epub 14-Jun-2022. ISSN 0120-8748.


The development of monoclonal antibodies (mAbs) against Calcitonin Gene Related Peptide (CGRP) has determined a new therapeutic era in migraine prophylaxis, demonstrating its effectiveness in patients with episodic migraine (EM) and chronic migraine (CM), obtaining a response in naive patients and in those who are refractory to multiple medications. A 50% decrease in migraine attacks per month during the first 3 months of use is the approximate outcome in 50% of patients receiving this therapy.


This consensus from the Colombian Association of Neurology (ACN) has the objective of serving as a guide for the rational use of antiCGRP mAbs in patients with EM and CM.


The headache committee through the application of the Delphi methodology and discussions in subsequent meetings, develops this consensus, supported in the published literature and expert recommendations.


Fourteen answers from headache experts were received regarding the use of drugs for migraine prophylaxis, analyzing their applicability in frequent clinical situations.


AntiCGRP mAbs have proved their effectiveness with adequate pathophysiological support, but with a high price in a highly prevalent disease, there is then a need to select the patient who best benefits from this therapy.


AntiCGRP mAbs are recommended in patients with EM and CM that have previously failed to other prophylactic drugs.

Palabras clave : Botulinum toxins Type A; Chronic pain; Headache; Migraine disorders; Monoclonal antibodies; Prevention and control (MeSH).

        · resumen en Español     · texto en Español     · Español ( pdf )